索引超出了数组界限。
1Zitomersky NL, Verhave M, Trenor CC 3rd. Thrombosis and inflammatory bowel disease: a call for improved awareness and prevention[J]. Inflamm Bowel Dis, 2011, 17(1): 458-470.
2Matowicka-Karna J. Markers of inflammation, activation of blood platelets and coagulation disorders in inflammatory bowel diseases[J]. Postepy Hig Med Dosw (Online), 2016, 70: 305-312.
3 中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见(2018年,北京)[J]. 中华消化杂志, 2018, 38(5):292-311.
4 姚萍, 陈玲, 孙健, 等. 外周血内PCT、CRP、ESR、PLT水平对炎症性肠病的预判价值分析[J]. 国际检验医学杂志, 2019, 40(22):2762-2766.
5 张怡, 王培学, 马晶晶, 等. 血清降钙素原评估炎症性肠病活动度107例初探[J]. 中华消化杂志, 2017, 37(4): 232-237.
6 倪向飞. 儿童炎症性肠病血小板和凝血指标变化及其与疾病活动度的关系[J]. 养生保健指南, 2021(7): 28.
7 苏仁玉, 黄蓓. 静脉输注英夫利昔单抗联合手术治疗克罗恩病肛瘘的疗效及对血小板计数等指标的影响[J]. 血栓与止血学, 2021, 27(6): 1007-1008.
8 程成全, 胡志坚. 血小板相关参数对评估炎症性肠病活动性的临床意义[J]. 实验与检验医学, 2020, 38(2): 248-252.
9Menees SB, Powell C, Kurlander J, et al. A meta-analysis of the utility of C-reactive protein, erythrocyte sedimentation rate, fecal calprotectin, and fecal lactoferrin to exclude inflammatory bowel disease in adults with IBS[J]. Am J Gastroenterol, 2015, 110(3): 444-454.
10 Norouzinia M, Chaleshi V, Alizadeh AHM, et al. Biomarkers in inflammatory bowel diseases: insight into diagnosis, prognosis and treatment[J]. Gastroenterol Hepatol Bed Bench, 2017, 10(3): 155-167.
11 Anka Idrissi D, Senhaji N, Aouiss A, et al. IL-1 and CD40/CD40L platelet complex: elements of induction of Crohn's disease and new therapeutic targets[J]. Arch Pharm Res, 2021, 44(1): 117-132.